Abstract 274P
Background
B-cell lymphoma is associated with an aggressive clinical course, is prone to rapid growth and early progression. Studying gene expression profiles to identify molecular subgroups of lymphomas is a topical issue of haematology as it allows a personalized approach to treatment with high-dose polychemotherapy (PCT) regime with a monoclonal antibody. Such approach improves the immediate treatment efficacy and event-free survival rate. Purpose of the study was to increase the efficacy of therapy in patients with non-Hodgkin large B-cell lymphoma based on the examination of molecular genetic features of the tumor and the use of polychemotherapy based on mutational gene expression profile.
Methods
In this single-center prospective study, 44 patients with non-Hodgkin large B-cell lymphomas stages II-IV A & B were treated at the Department of Hemoblastosis at Kazakh Institute of Oncology and Radiology. Patients with mutated c-MYC gene were treated by high-dose PCT with R+HyperCVAD and we have analysed the treatment outcome.
Results
The FISH test revealed a mutation of c-MYC gene in non-Hodgkin large B-cell lymphoma patients. Therefore, these cases were classified as highly malignant and required high-dose PCT with a monoclonal antibody Rituximab followed by stem cell autotransplantation. This regime of PCT has improved the immediate efficacy of treatment. The patients (18 men and 26 women) were aged 27 to 58 years, with an average age of 42 years. B-cell lymphoma was confirmed in all cases; the complete response amounted to 80.0%; the disease-free survival (DFS) was 18 months (95% CI, 6.592-25.762, P = 0.003).
Conclusions
High-dose PCT in the R+HyperCVAD regimen (3-4 courses) followed by immunotherapy and autotransplantation of hemopoietic stem cells in patients with non-Hodgkin B-cell lymphoma have improved the immediate efficacy and long-term results of treatment of B-cell non-Hodgkin lymphoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Kazakh Institute of Oncology and Radiology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
511P - Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)
Presenter: Toshio Kubo
Session: Poster display session
Resources:
Abstract
485P - A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
Presenter: Seong Hoon Yoon
Session: Poster display session
Resources:
Abstract
522P - Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer
Presenter: Hajime Oi
Session: Poster display session
Resources:
Abstract
512P - A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer
Presenter: Hisao Imai
Session: Poster display session
Resources:
Abstract
497P - Real-word efficacy of osimertinib in patients with metastatic EGFRm NSCLC: An interim analysis from a multi-center study in China
Presenter: Xiangyun Ye
Session: Poster display session
Resources:
Abstract
507P - Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study
Presenter: Takeshi Uenami
Session: Poster display session
Resources:
Abstract
516P - Clinical outcomes in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan
Presenter: Masahiro Shimada
Session: Poster display session
Resources:
Abstract
486P - Phase II study of low-dose afatinib maintenance treatment for patients with EGFR-mutated non-small cell lung cancer (NJLCG1601)
Presenter: Mami Morita
Session: Poster display session
Resources:
Abstract
515P - Polypharmacy as a prognostic factor in elderly patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
Presenter: Taiki Hakozaki
Session: Poster display session
Resources:
Abstract
518P - Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer
Presenter: Beung chul Ahn
Session: Poster display session
Resources:
Abstract